PGNY — Progyny, Inc.

Is PGNY overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Healthcare Plans

Oversold As of October 3, 2026

Progyny, Inc. (PGNY) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Healthcare Plans) last closed at $25.23. The rating moved from Neutral to Oversold on September 23, 2026.

See all oversold Healthcare stocks →

AI analysis

Progyny operates a differentiated fertility and family-forming benefits platform with strong employer adoption dynamics and sticky multi-year contracts. The company benefits from outcomes-focused care coordination and a data-enabled approach that can deliver cost predictability and customer retention. Growth opportunities include deeper penetration of large employers, product/service expansion and cross-sell of virtual/diagnostic offerings. Near-term headwinds include macro-driven benefit spend sensitivity, competitive bundling by large carriers, potential client concentration, and a cautious capital markets backdrop for digital-health businesses. Absent fresh company-specific catalysts or clearer margin improvement, expect measured upside but heightened sensitivity to macro and payor pressures.

Key factors

  • Market-leading position in employer fertility and family-forming benefits with a differentiated clinical care model and case-management approach
  • High stickiness of employer contracts and potential for multi-year, recurring revenue from large corporate clients
  • Data-driven platform that can drive improved clinical outcomes and cost predictability versus traditional benefits, supporting pricing leverage with some customers
  • Ongoing secular demand for fertility and family-forming benefits among employers as talent/retention tool, supporting TAM expansion
  • Opportunities to expand services (e.g., virtual care, family-forming services, diagnostic partnerships) and cross-sell into existing clients
  • Recent broader market risk-off tone (digital-health IPO cooling) that can constrain access to capital and depress valuations across health-tech peers in the near term

Risks

  • Exposure to employer benefit budgets and macro sensitivity: slower hiring/cost-cutting could reduce new contract wins or slow renewals
  • Payor and purchaser pricing pressure from large insurers, PBMs and self-funded employers seeking cheaper alternatives or in-house solutions
  • Concentration risk if a meaningful portion of revenue is tied to a handful of large clients; client loss or renegotiation could materially impact near-term revenue
  • Regulatory and policy risk (state and federal): changes to coverage mandates, reimbursement frameworks or program funding could alter demand or pricing
  • Competitive risk from large carriers, benefits platforms and vertical players that could bundle fertility services into broader offerings
  • Execution risk on margin expansion and international or product expansion given historical investment in growth and potential incremental SG&A
  • Limited publicly available, up-to-date social/research signals in this dataset increases uncertainty about near-term market perception

See today's live rating, score and targets

Members see the live hourly rating for PGNY — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.